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Abstract
The NIMH Research Domain Criteria (RDoC) initiative aims to describe key dimensional 
constructs underlying mental function across multiple units of analysis—from genes to observable 
behaviors—in order to better understand psychopathology. The acute threat (“fear”) construct of 
the RDoC Negative Valence System has been studied extensively from a translational perspective, 
and is highly pertinent to numerous psychiatric conditions, including anxiety and trauma-related 
disorders. We examined genetic contributions to the construct of acute threat at two units of 
analysis within the RDoC framework: 1) neural circuits and 2) physiology. Specifically, we 
focused on genetic influences on activation patterns of frontolimbic neural circuitry and on startle, 
skin conductance, and heart rate responses. Research on the heritability of activation in threat-
related frontolimbic neural circuitry is lacking, but physiological indicators of acute threat have 
been found to be moderately heritable (35-50%). Genetic studies of the neural circuitry and 
physiology of acute threat have almost exclusively relied on the candidate gene method and, as in 
the broader psychiatric genetics literature, most findings have failed to replicate. The most robust 
support has been demonstrated for associations between variation in the serotonin transporter 
(SLC6A4) and catechol-O-methyltransferase (COMT) genes with threat-related neural activation 
and physiological responses. However, unbiased genome-wide approaches using very large 
samples are needed for gene discovery, and these can be accomplished with collaborative 
consortium-based research efforts, such as those of the Psychiatric Genomics Consortium (PGC) 
and Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium.
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Psychiatric disorders are heritable (Kendler and Eaves, 2005), and studying their genetic 
basis has the potential to increase our understanding of risk for these conditions and inform 
intervention efforts. Over the years, the literature on the genetics of psychiatric syndromes 
has grown dramatically, particularly within the past decade (see Sullivan et al., 2012, for a 
review). Although replicable genetic findings have been detected for schizophrenia and 
bipolar disorder (e.g., Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; 
Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011; Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014), mapping the complex 
genetic architecture of psychiatric conditions is far from complete. Additional research is 
needed, and there have been calls for developing approaches that go beyond examining 
psychiatric diagnoses as defined by the current nosology in order to facilitate discovery of 
genetic mechanisms of psychiatric risk (e.g., Meyer-Lindenberg and Weinberger, 2006).
The Research Domain Criteria (RDoC) Project
The Research Domain Criteria (RDoC) project, spearheaded by the National Institute of 
Mental Health (NIMH), represents one such alternative approach. The RDoC research 
framework postulates that psychiatric conditions are disorders of brain circuits, and it 
emphasizes the study of neurobiological mechanisms that cut across psychiatric disorders as 
defined by current diagnostic classification systems (Morris and Cuthbert, 2012). With the 
RDoC approach, psychopathology is classified based on underlying dimensions of function 
that can be defined at multiple units of analysis, ranging from genes to molecules to neural 
circuits to physiology to observable behaviors (Cuthbert and Insel, 2013). These dimensions 
(or constructs) are grouped into major domains of functioning that reflect key aspects of 
motivation, cognition, and social behavior (e.g., Negative Valence Systems, Cognitive 
Systems). One of the ultimate goals of the RDoC initiative is to use the neurobiological data 
that characterize these dimensions to develop “biosignatures” of psychopathology that can 
then be utilized to guide clinical interventions (Morris and Cuthbert, 2012).
By focusing on the identification and characterization of neurobiological intermediate 
phenotypes that underlie psychiatric syndromes, the RDoC framework has promise for 
furthering our understanding of the genetic basis of psychopathology. Psychiatric disorders 
are complex phenotypes that are influenced by the contributions of multiple genetic variants 
of small effects (Sullivan et al., 2012). The effects of genes are not expressed directly at the 
level of the behavioral manifestations of psychiatric syndromes (Fisher et al., 2008), which 
limits the detection of associations with risk variants. In contrast, neurobiological 
intermediate phenotypes are proposed to lie closer to the underlying genetic architecture 
than more distal clinical outcomes, and thus it may be easier to identify links between 
genetic loci and intermediate phenotypes due to higher penetrance (Meyer-Lindenberg and 
Weinberger, 2006). Nevertheless, effect sizes observed for individual single nucleotide 
polymorphisms (SNPs) on intermediate phenotypes are likely to be modest (e.g., Stein et al., 
2012) and still require large sample sizes to be adequately powered. In addition, researchers 
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have postulated that intermediate phenotypes should be observable in genetically vulnerable 
individuals who do not exhibit the symptoms of a psychiatric disorder (Meyer-Lindenberg 
and Weinberger, 2006). Studying genetic influences on quantitative traits that are related to 
clinical phenotypes and index underlying biological processes more directly than disorders 
thus has potential for mapping the genetic architecture of psychopathology.
Aims of the Review
Although the RDoC project is a relatively recent initiative that aims to guide future research 
efforts, a number of findings in the extant literature can be organized in terms of this 
framework. As noted above, RDoC emphasizes several systems, which comprise different 
constructs. The acute threat (“fear”) construct of the Negative Valence System has been 
studied extensively from a translational perspective, with research conducted in both 
animals and humans. Not only is the acute threat construct highly pertinent to numerous 
psychiatric conditions, including various anxiety and trauma-related disorders, but it is also 
directly relevant to exposure therapy, the most effective treatment at present for fear and 
anxiety (Briscione et al., 2014; Institute of Medicine, 2008). Therefore, studying acute threat 
has the potential to impact understanding of various manifestations of psychopathology and 
inform clinical applications.
In this review, we focus on genetic contributions to the construct of acute threat at two units 
of analysis of the RDoC framework: 1) neural circuits and 2) physiology. First, we introduce 
relevant paradigms for the study of acute threat. Next, we summarize findings on the 
heritability of and molecular genetic influences on the neural and physiological bases of 
acute threat, focusing on findings from functional neuroimaging and physiology studies in 
humans. Finally, we make recommendations for future studies in order to address gaps in 
the extant literature, and we link the existing research base to the goals of the RDoC 
initiative.
The literatures on the neural and physiological bases of acute threat are closely related, and 
much research on the physiology of acute threat has focused on understanding how it aligns 
with underlying neural circuitry. Furthermore, neural and physiological indicators of acute 
threat have been shown to have substantial inter-individual variability (Baas, 2013), thereby 
permitting investigations along the entire range of these quantitative measures. Thus, 
studying genetic influences on the neural circuits and physiology of acute threat offers a 
prime opportunity for conducting a cross-cutting examination of dimensions of threat 
responses that can help to shed light on biological mechanisms of risk for and resilience to 
mental illness.
In the current paper, we survey papers on genetic influences on the neural and physiological 
underpinnings of acute threat that were published between 1995 and December 31, 2014. 
The following keywords were used in our literature search: genetics - fear - physiology - 
circuits - neural - brain - conditioning - extinction. Several relevant reviews on this topic 
have been published in recent years (e.g., Lonsdorf and Kalisch, 2011; Murphy et al., 2013). 
Although the current paper is comprehensive, it is not an exhaustive review, and we refer the 
reader to those papers for additional coverage of this topic. As described below, and 
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summarized in Table I, the vast majority of studies have examined biologically plausible 
candidate genetic variants that are thought to have neurochemical effects on the acute threat 
system or that have been associated with psychiatric disorders characterized by acute threat. 
Furthermore, consistent with the notion that intermediate phenotypes should be observable 
in genetically vulnerable individuals who do not exhibit the symptoms of a psychiatric 
disorder (Meyer-Lindenberg and Weinberger, 2006), almost all investigations have been 
conducted in individuals without a history of psychopathology (some exceptions are noted, 
however). Although the studies reviewed differ in the samples, genetic variants, and 
paradigms examined, they are united by the common goal of identifying the biological 
intermediates that translate genetic risk into behavior.
Paradigms for the Study of Acute Threat
The acute threat construct has been investigated predominantly in the context of two 
particular scientific paradigms: 1) fear conditioning paradigms and 2) aversive picture 
processing paradigms. Fear conditioning paradigms are based on the principles of Pavlovian 
conditioning (Maren, 2001; Pavlov, 1927). Specifically, they involve the pairing of a neutral 
stimulus with an aversive unconditioned stimulus (US). With repeated pairings, the neutral 
stimulus elicits the same type of response as the US and becomes a conditioned stimulus 
(CS). The response evoked by the CS is termed the fear-conditioned response (CR), whereas 
the response evoked by the US is the unconditioned response (UR). Fear conditioning 
paradigms permit the study of several threat-related processes, including fear acquisition, 
fear inhibition, fear generalization, and fear extinction. Fear acquisition refers to the extent 
to which levels of fear responding to the CS are greater than those during baseline or inter-
trial intervals (Lissek et al., 2005). Simple conditioning paradigms traditionally employ only 
one CS. In contrast, differential fear conditioning paradigms generally use two CSs: the CS+ 
is paired with the US and functions as a “danger signal,” whereas the CS- is not paired with 
the US and is a “safety signal” (Lissek et al., 2005). Comparing the CRs in response to the 
CS+ vs. the CS- permits an examination of whether individuals can discriminate between 
predictors of danger and safety. Fear inhibition is thought to occur when a fear response is 
suppressed in the context of safety cues (Lissek et al., 2005). Inhibition can be assessed by 
examining discrimination to the CS+ vs. CS- or by presenting the CS+ in conjunction with a 
neutral, safe stimulus. A recent meta-analysis of fear in anxiety disorders reported that 
heightened fear responses to safety cues is a robust finding in these patients (Duits et al., 
2015). Fear generalization refers to when stimuli that are similar to the CS+ also come to 
elicit the CR (Lissek et al., 2010; Norrholm et al., 2014). Fear extinction represents new 
learning that occurs when a previously reinforced CS+ is presented repeatedly without the 
US. This new extinction learning is thought to co-exist with the original fear memory 
(Sotres-Bayon and Quirk, 2010). High levels of fear during early extinction learning are 
thought to reflect persistent excitation, whereas high levels of fear during late extinction 
learning are thought to reflect deficits in fear inhibition (Norrholm et al., 2011).
The other major paradigm employed in studies of acute threat is aversive picture processing. 
In this task, individuals are presented with aversive pictures, often emotional faces (e.g., 
fearful or angry faces) or standardized unpleasant images from the International Affective 
Picture System (IAPS; Lang et al., 1999). Individuals typically passively view these images 
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(e.g., Stevens et al., 2014; Whalen et al., 2001), match the affect of an image with a target 
image (e.g., Hariri et al., 2002), or rate their fear in response to the images (e.g., Lau et al., 
2010). Responses to the aversive pictures are compared to responses to control stimuli (e.g., 
neutral images).
Whereas fear conditioning paradigms permit an examination of influences on multiple 
aspects of fear responding, including acquisition of fear, generalization of fear to other 
stimuli, and extinction of fear, aversive picture processing paradigms primarily provide a 
window on how individuals respond to aversive stimuli. That is, unlike aversive picture 
processing paradigms, fear conditioning paradigms offer more of an opportunity to 
understand associative learning as it underlies threat responses. In addition, fear 
conditioning paradigms have frequently been employed in animal studies of acute threat, 
thereby permitting greater comparison of findings from animal models and investigations in 
humans.
Neural Circuitry of Acute Threat
The neural basis of acute threat has been studied extensively, and our understanding of fear 
circuitry in humans stems, in large part, from work conducted in animals (Shin and 
Liberzon, 2010). Based on this work, frontolimbic circuitry has been identified as playing a 
key role in threat responses. Critical components of this circuitry include the amygdala, 
hippocampus, anterior cingulate cortex (ACC), insula, and ventromedial prefrontal cortex 
(PFC; see Shin and Liberzon, 2010, for a review). For example, the amygdala is integral for 
the acquisition of fear, and activation of the ACC, insula, and hippocampus have also been 
implicated in fear conditioning. The ventromedial PFC plays an important role in extinction 
learning, and research suggests that the hippocampus may be involved in the contextual 
modulation of extinction (Milad et al., 2007). Furthermore, connections between these brain 
regions have important implications for responses to acute threat. For example, the medial 
PFC and ACC have an inhibitory influence on subcortical regions, such as the amygdala, 
and this regulatory effect is thought to occur during fear extinction (e.g., Milad et al., 2007).
Genetic Influences on the Neural Circuitry of Acute Threat
Heritability
Although findings from twin studies suggest that brain volume is heritable, with meta-
analytic evidence indicating that brain structure is under strong genetic control (Blokland et 
al., 2012), the heritability of functional imaging phenotypes has received relatively little 
empirical investigation. As reviewed by Blokland et al. (2012), a few investigations have 
examined the heritability of task-related brain activity, although results across studies have 
been mixed. Functional activation in brain areas related to working memory circuits, 
including frontal areas and the middle cingulate cortex, has been found to be moderately 
heritable, with estimates ranging from 40-65% (Blokland et al., 2011; Koten et al., 2009), 
and there is initial evidence demonstrating the heritability of brain connectivity patterns 
(Shen et al., 2014). However, heritability estimates for activation in a number of regions of 
interest (ROIs) relevant to acute threat neural circuitry (e.g., the amygdala) in humans are 
lacking. Some functional neuroimaging work in monozygotic twins has examined 
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frontolimbic regions (Miskowiak et al., 2014; Wolfensberger et al., 2008), and reactivity in 
ROIs implicated in acute threat (e.g., the amygdala) has been found to be stable and trait-
like (e.g., Manuck et al., 2007). Nevertheless, behavioral genetics research is needed that 
directly addresses the heritability of activation in these areas.
Molecular genetics findings: Candidate gene studies
There is a growing body of work demonstrating associations between variation in candidate 
genes and activation of the neural circuitry related to acute threat responses. As shown in 
Table I, most studies by far have examined the 5-HTTLPR polymorphism in the promoter 
region of the serotonin transporter (SLC6A4) gene and the Val158Met polymorphism of the 
catechol-O-methyltransferase (COMT) gene, although additional genes have been 
considered as well. Even though we present all candidate gene findings in Table I, we limit 
our discussion in the text to only those that have been investigated in two or more 
independent studies. We first focus on serotonergic- and dopaminergic-related genes more 
broadly and then discuss results from some additional genes that have been investigated.
Serotonin has been identified as an important modulator of the corticolimbic circuit 
underlying acute threat (Fisher and Hariri, 2013), and several serotonergic-related genes 
have been studied with respect to the neural basis of acute threat, including the serotonin 
transporter (SLC6A4), tryptophan hydroxylase 2 (TPH2), monoamine oxidase A (MAOA), 
and serotonin 1A receptor (HTR1A) genes. As noted above, the 5-HTTLPR polymorphism of 
SLC6A4 has received the greatest empirical attention. SLC6A4 is involved in the regulation 
of reuptake of serotonin to the presynaptic neuron (Homberg and Lesch, 2011), and 5-
HTTLPR is a functional 44-base pair insertion/deletion polymorphism in the promoter 
region of the gene. 5-HTTLPR has two common alleles: short (S) and long (L). Compared to 
the L allele, the S allele has been associated with reduced serotonin transporter protein 
availability and function and, consequently, higher synaptic serotonin concentrations 
(Homberg and Lesch, 2011). Some research also suggests that an A/G single SNP (rs25531) 
upstream of 5-HTTLPR may modify the function of L alleles, such that the LG allele is 
associated with decreased transcriptional efficiency that is similar to that of the S allele (e.g., 
Hu et al., 2006). Whereas some research has examined a biallelic classification of 5-
HTTLPR (i.e., S vs. L alleles), other work has considered a triallelic classification whereby S 
and LG alleles are compared to LA alleles. Although we refer to the S and L alleles below 
for simplicity, we note that some of this research is based on comparisons of the S/LG vs. LA 
alleles.
Across numerous studies, there is evidence that, compared to the L allele, the S allele of 5-
HTTLPR is associated with greater activation in several frontolimbic areas implicated in 
acute threat, including the amygdala, hippocampus, cingulate gyrus, medial PFC, and ACC, 
in response to processing of aversive vs. neutral stimuli (e.g., Bertolino et al., 2005; Hariri et 
al., 2002; Heinz et al., 2005; Lonsdorf et al., 2011; Smolka et al., 2007; Surguladze et al., 
2008; Williams et al., 2009). Furthermore, research suggests that 5-HTTLPR genotype is 
also characterized by differential patterns of brain connectivity in frontolimbic neural 
circuitry (e.g., Heinz et al., 2005; Pezawas et al., 2005; Surguladze et al., 2008). The 
association between 5-HTTLPR genotype and amygdala activation has been especially well-
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supported. A recent meta-analysis of 34 independent samples demonstrated support for a 
statistically significant association between 5-HTTLPR genotype and both left (Hedge's g = 
0.22) and right (Hedge's g = 0.21) amygdala activation in response to affective stimuli 
(Murphy et al., 2013). However, effect sizes were small; approximately 1% of the variance 
in amygdala activation was estimated to be accounted for by 5-HTTLPR genotype. This 
estimate is smaller than the percentage of amygdala activation explained by 5-HTTLPR 
variation (10%) in a previous meta-analysis (Munafò et al., 2008). Interestingly, differences 
in study design (e.g., imaging method, task requirements, stimulus type) or sample 
composition (e.g., ancestry, patient vs. non-patient population) were not found to account for 
the between-study heterogeneity observed in effect sizes, although statistical power was 
often low for these comparisons (Murphy et al., 2013). Murphy et al. (2013) suggested that 
inadequate sample sizes most likely contributed to variability in effect size across 
investigations. Indeed, all published studies to date were found to be statistically 
underpowered to demonstrate an association between 5-HTTLPR genotype and amygdala 
activation.
Although small in effect size, the association between 5-HTTLPR genotype and amygdala 
activation appears to be robust. However, what drives the S allele-amygdala activity relation 
is not entirely clear. For example, some research suggests that the link between 5-HTTLPR 
genotype and amygdala response is due to differences in activation to neutral or control 
stimuli, rather than to increased reactivity to aversive stimuli (e.g., Canli et al., 2005b; Canli 
et al., 2006), although findings are somewhat inconsistent across studies. More research is 
needed to better understand what underlies the association between 5-HTTLPR genotype and 
amygdala activation. Additional research is also needed to better comprehend the time 
course of 5-HTTLPR-related differences in frontolimbic activation, as initial evidence 
suggests a lack of amygdala habituation to aversive faces over time for S allele carriers but 
not L allele homozygotes (Lonsdorf et al., 2011).
Most research has examined the link between 5-HTTLPR genotype and neural activation 
during aversive picture processing, but a handful of studies have investigated 5-HTTLPR 
genotype and neural responses to fear conditioning paradigms. In this work, compared to the 
L allele, the S allele has been associated with greater reactivity in fear network regions (e.g., 
amygdala, insula, thalamus, occipital cortex, dorsomedial PFC) during fear conditioning 
(Klucken et al., 2013; Klucken et al., 2014; Klumpers et al., 2014), elevated amygdala-
insula coupling during fear conditioning (Klucken et al., 2014), and stronger late 
conditioned and unconditioned responses in the right insula during fear conditioning 
(Hermann et al., 2012).
As is characteristic of the broader literature on genetic influences on the neural circuitry of 
acute threat, the vast majority of research on 5-HTTLPR genotype and acute threat neural 
response has been conducted in adults without a history of psychopathology (e.g., Klucken 
et al., 2013; Klucken et al., 2014; Murphy et al., 2013). However, there is some evidence 
that the S allele is associated with increased amygdala activation to clinically relevant 
triggers in individuals with psychopathology. For example, in one study, S allele carriers 
with social phobia exhibited greater amygdala activation in response to a public speaking 
task than L allele homozygotes (Furmark et al., 2004). Furthermore, initial findings in 
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healthy children and adolescents indicated that S allele carriers exhibited greater activation 
in limbic, parietal, and frontal regions in response to negative stimuli compared to L allele 
homozygotes, which suggests that the association between 5-HTTLPR genotype and 
frontolimbic neural activation is present earlier in development (Thomason et al., 2010).
Some studies have also begun to examine whether the association between 5-HTTLPR 
genotype and neural activation is moderated by the environment. There is some initial 
support that S allele carriers who also report high levels of life stress exhibit the greatest 
levels of reactivity in acute threat-related neural regions during processing of emotional 
stimuli and fear conditioning (e.g., Klucken et al., 2013; Williams et al., 2009). However, 
not all studies have demonstrated this pattern of results (e.g., Canli et al., 2006). Differences 
in the environmental variables examined across these few investigations (e.g., early life 
stress vs. lifetime stressful life events) and variation in the paradigms and comparisons used 
make it difficult to draw conclusions. More research is needed, but there is at least initial 
support for the presence of Gene × Environment interactions for 5-HTTLPR variation and 
neural activity related to acute threat.
Although the literature on other serotonergic-related genes and the neural circuitry of acute 
threat is smaller than the body of work on 5-HTTLPR, there is some support for associations 
with TPH2, MAOA, and HTR1A. Specifically, a SNP (rs4570625) in the promoter region of 
the TPH2 gene, which encodes a rate-limiting enzyme involved in the synthesis of serotonin 
in the brain (Walther et al., 2003; Zill et al., 2004), has been linked to amygdala reactivity to 
emotional stimuli, such that T allele carriers exhibit greater amygdala activation to 
emotional stimuli than G allele homozygotes (Brown et al., 2005; Canli et al., 2005a; Canli 
et al., 2008). Furthermore, the association between the T allele of rs4570625 with greater 
amygdala activation during fear conditioning was potentiated among individuals reporting a 
higher number of traumatic events (Hermann et al., 2012).
Variation in MAOA, a gene involved in the degradation of serotonin, has also been linked to 
threat-related neural activation. A variable number tandem repeat (VNTR) polymorphism in 
the promoter region of MAOA has been identified that has higher expression (i.e., associated 
with increased transcription and therefore greater breakdown of serotonin) and lower 
expression variants (Deckert et al., 1999; Sabol et al., 1998). Compared to the higher 
expression variant, the lower expression variant has been associated with increased limbic 
activation to aversive stimuli in individuals without a history of psychopathology (Meyer-
Lindenberg et al., 2006). Additionally, in a sample of patients with panic disorder with 
agoraphobia, those with the low expression variant showed increased neural responses to the 
CS+ vs. CS- during fear acquisition in the ACC, precuneus, and left parahippocampus 
compared to individuals with the high expression variant (Reif et al., 2014). Furthermore, 
the low expression group also showed patterns of neural activation consistent with improved 
discrimination between the CS+ and CS- after completing 12 weeks of cognitive behavioral 
therapy (CBT). In contrast, the high expression group did not exhibit such evidence of 
differential neural responses to the CS+ vs. CS- after CBT, which may reflect fear 
overgeneralization processes at the neural level.
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Components of the neural circuitry of fear (e.g., the amygdala and ACC) are also influenced 
by serotonin 1A receptor-mediated serotonergic signaling. The serotonin 1A receptor is a 
major inhibitory serotonergic receptor in the brain, with high density of the receptor in 
cortical and subcortical regions, including limbic areas (Varnas et al., 2004). Compared to 
the C allele, the G allele of a functional SNP in the promoter region of HTR1A (rs6295) has 
been associated with reduced serotonergic signaling (Lemonde et al., 2003), and there is 
initial evidence linking HTR1A variation to amygdala activation. In healthy individuals, C 
allele homozygotes exhibited increased amygdala activation to emotional faces vs. shapes 
compared to G allele carriers (Fakra et al., 2009). However, in a sample of patients with 
panic disorder with agoraphobia, G allele homozygotes exhibited greater amygdala activity 
to threat and safety cues during early acquisition of fear conditioning (Straube et al., 2014). 
In addition, patients homozygous for the G allele showed diminished effects of 12 sessions 
of CBT on neural correlates of fear conditioning, whereas C allele homozygotes exhibited 
changes in neural responses in these areas after CBT consistent with differential 
conditioning (Straube et al., 2014). Differences in the nature of the samples (i.e., individuals 
with vs. without psychopathology) and paradigms (i.e., emotional processing vs. fear 
conditioning tasks) make it challenging to compare the results of these two studies. 
Nevertheless, these investigations provide preliminary evidence that HTR1A variation may 
influence threat-related processes at the neural level, although additional work is needed to 
better understand this association.
Dopaminergic-related genes have also been of interest when examining genetic influences 
on the neurocircuitry of acute threat given that dopamine has been shown to play a key role 
in fear conditioning, especially with respect to fear memory stabilization (Fadok et al., 2009; 
Pezze and Feldon, 2004). The COMT gene is involved in the degradation of dopamine, 
particularly in the prefrontal cortex (Mannisto and Kaakkola, 1999). Several studies have 
examined patterns of acute threat-related neural activation that are associated with a 
functional A/G SNP in COMT (rs4680) that results in the substitution of valine (Val) by 
methionine (Met) at codon 158 (the Val158Met polymorphism). Compared to the Val allele, 
the Met allele is associated with lower enzymatic activity and, consequently, higher 
dopamine levels (Mannisto and Kaakkola, 1999), and it has been characterized by greater 
activation in frontolimbic regions (e.g., the amygdala, hippocampus, cingulate gyrus, and 
dorsal and ventrolateral PFC) in response to aversive stimuli (Drabant et al., 2006; Lonsdorf 
et al., 2011; Smolka et al., 2005; Smolka et al., 2007; Williams et al., 2010). There is also 
initial evidence of increased functional coupling between limbic and prefrontal regions in 
Met allele homozygotes (Drabant et al., 2006).
One exception to this overall body of work comes from a study by Kempton et al. (2008), 
which found a different pattern of association between COMT genotype and neural 
reactivity to fearful faces when considering interactions with gender (given that estrogen 
reduces COMT activity). In this investigation, the Val/Val genotype was associated with 
increased limbic response during fearful affect recognition compared to the Met/Met 
genotype, primarily in females. Most research has been conducted in adults without a history 
of psychopathology, but in one study of patients with panic disorder, Val allele carriers 
(compared to Met allele homozygotes) exhibited greater amygdala activation to fearful faces 
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(Domschke et al., 2008). Although preliminary, the findings of Kempton et al. (2008) and 
Domschke et al. (2008) suggest that differential associations between COMT genotype and 
activation of acute threat neural circuitry may emerge when considering gender and 
psychopathology as potential moderators.
Several additional genes have been explored with respect to acute threat-related neural 
circuitry, often based on preclinical findings that hold promise for understanding threat-
related processes in humans. For example, genes related to memory consolidation and 
stabilization have emerged as candidates of interest given their roles in processes related to 
fear memory formation. One such gene is the brain-derived neurotrophic factor (BDNF) 
gene, which codes for the BDNF growth-factor protein. The BDNF growth-factor protein 
plays an important role in neuronal survival and learning and memory via its regulatory 
influence on synaptic plasticity (Bath and Lee, 2006). A SNP in the BDNF gene (rs6265) 
that results in a valine to methionine amino acid substitution at codon 66 (the Val66Met 
polymorphism) has been found to alter the intracellular processing of BDNF, with the Met 
allele associated with less secretion of BDNF and reduced hippocampal synaptic activity 
compared to the Val allele (Egan et al., 2003). Growing evidence suggests that carriers of 
the Met allele exhibit greater activation of limbic fear circuitry (e.g., the amygdala, 
hippocampus, insula) during fear conditioning and extinction compared to Val allele 
homozygotes (Lonsdorf et al., 2014; Soliman et al., 2010). Furthermore, there is an initial 
finding that the Met allele is associated with reduced vmPFC activation during extinction 
compared to the Val allele (Soliman et al., 2010), a pattern of neural activation suggestive of 
weaker fear extinction. However, the incorporation of a reversal learning phase prior to 
extinction training complicates interpretation of this extinction finding.
Additional work is also needed regarding the time course by which variation in BDNF 
influences neural activation during extinction, as some initial research has found that BDNF 
genetic variation is differentially associated with neural activation during extinction 
primarily during early extinction trials (Lonsdorf et al., 2014). Furthermore, although prior 
research has detected associations between the Val66Met polymorphism and neural 
activation during threat-related processing in adults without any history of psychopathology 
(Lonsdorf et al., 2014; Soliman et al., 2010), one study in adolescents found that Met allele 
carriers (compared to Val allele homozygotes) exhibited increased amygdala and 
hippocampal activation during emotional processing only in individuals with anxiety 
disorders or unipolar depression (Lau et al., 2010). This finding suggests that associations 
between BDNF Val66Met genotype and activation of acute threat-related neural circuitry 
may be more pronounced in individuals with psychopathology, although more research is 
needed to better understand this issue.
Translational work has also suggested a role for neuropeptide S (NPS) and its G-protein 
coupled receptor (NPSR1) in fear responding, with findings from animal models indicating 
that NPS has anxiolytic effects on the central nervous system (Pape et al., 2010). As a result, 
researchers have been interested in whether variation in the neuropeptide S receptor 1 
(NPSR1) gene is associated with acute threat-related neural circuitry. Compared to the A 
allele, the T allele of the rs324981 SNP in NPSR1 is characterized by greater NPSR 
expression and NPS efficacy at the receptor, although binding affinity is not affected 
Sumner et al. Page 10









(Reinscheid et al., 2005). Interestingly, in contrast to animal research suggesting an 
anxiolytic effect of NPS, in humans, the T allele has been associated with exaggerated fear 
responses at the neural level. Specifically, the T allele has been linked to stronger ACC and 
dorsomedial PFC activation to the CS+ during fear acquisition (Raczka et al., 2010) and to 
greater amygdala responsiveness to negative faces (vs. shapes; Dannlowski et al., 2011). In a 
sample of individuals with panic disorder, the T allele was associated with decreased 
dorsolateral PFC, lateral orbitofrontal cortex, and ACC activation when processing fearful 
faces (vs. a control shape stimulus), although no significant differences were observed for 
amygdala activation (Domschke et al., 2011). Tupak et al. (2013) also examined rs324981 
variation with respect to activation in the medial and dorsolateral PFC during an emotional 
Stroop task. Only A allele homozygotes, and not T allele carriers, exhibited increased 
activation to fear-relevant (vs. neutral) stimuli in the medial and dorsolateral PFC during the 
task (i.e., only those homozygous for the A allele showed an emotional Stroop effect). These 
results may reflect an adaptive inhibitory emotional regulation response to threat that was 
present in those with the A/A genotype but was less efficient in T allele carriers. Despite 
differences in the paradigms employed (e.g., fear conditioning vs. processing of emotional 
stimuli), overall findings from these studies begin to suggest that the T allele of the 
rs324981 SNP may be associated with heightened neural reactivity to fearful stimuli, as 
reflected by greater amygdala activation and less prefrontal inhibitory activity.
Preclinical work has also implicated the endocannabinoid system in threat-related processes, 
with the endocannabinoid anandamide in the amygdala implicated in fear extinction in 
particular (Gunduz-Cinar et al., 2013). Anandamide is degraded by fatty acid amide 
hydrolase (FAAH; Spradley et al., 2010), which is encoded by the FAAH gene. Two studies 
have linked the lower-expressing A allele of the rs324420 SNP in FAAH to threat-related 
amygdala activation, with one investigation demonstrating blunted amygdala reactivity to 
threatening faces (Hariri et al., 2009) and another indicating quicker habituation of the 
amygdala to aversive faces (Gunduz-Cinar et al., 2013).
Gene × Gene interactions—Most studies have examined the association between 
variation in a single candidate gene with acute threat-related neural activation, but a few 
studies have considered the contributions of multiple genes in a single investigation. The 
influence of genes is rarely limited to a single biological system, and there is often cross-talk 
between genes and/or systems that may, in turn, contribute to acute threat-related processes. 
Examining the joint contributions of genetic variants from multiple biological systems is 
thus of interest, and this approach is consistent with the notion that activation of the neural 
circuitry underlying threat processes is polygenic. Two studies found support for additive 
effects of variation in two serotonergic-related genes (TPH2 and 5-HTTLPR) on neural 
activity. Canli et al. (2008) detected additive effects of the TPH2 T allele and 5-HTTLPR S 
allele on putamen and amygdala activation to emotional stimuli, such that effects were 
amplified when both genotypes, rather than just a single gene, were examined. In addition, 
Hermann et al. (2012) found a combined effect of the TPH2 T allele and 5-HTTLPR S allele 
on increased activation of the dorsal ACC during extinction, which may suggest prolonged 
fear expression. Even though formal tests of Gene × Gene interactions were not significant 
in these studies, these findings nevertheless suggest that considering the contributions of 
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multiple genetic variants, including those related to the same family of neurotransmitters, 
may increase our understanding of genetic influences on the neural circuitry of acute threat 
and shed light on underlying mechanisms.
Physiology of Acute Threat
As noted above, the neural circuitry of acute threat is aligned with physiological processes, 
and several physiological metrics have been used to assess the construct of acute threat, 
including startle, skin conductance, and heart rate responses. The startle response is a 
frequently used translational methodology for measuring learned fear and basic defensive 
physiology in response to threat (Briscione et al., 2014). Two distinct, yet interrelated, 
circuits underlie the startle response: 1) a basic reflex response that is initiated by the 
nucleus reticularis pontis caudalis (Davis et al., 1982), and 2) a modulatory influence on the 
reflex by the amygdala (Davis et al., 1997). Startle is typically assessed by measuring the 
strength of the eye blink (as indexed by electromyographic activity from the orbicularis 
oculi muscle) in response to a startle probe (e.g., a loud noise or air puff; e.g., Norrholm et 
al., 2013; Vaidyanathan et al., 2014). The overall startle response provides a baseline index 
of startle reactivity, and startle can be modulated by the presence of emotional stimuli. For 
example, potentiation of the startle response occurs in the presence of aversive stimuli, and 
this response (known as fear-potentiated startle) is of particular interest with respect to 
threat-related processes. This potentiation is influenced by the amygdala, and it occurs 
independently of cortical influences, thereby providing a measure of threat responding that 
is distinct from cognition (Davis, 1992). A variety of threatening cues have been found to 
potentiate the startle response in humans, including aversive images (e.g., Klauke et al., 
2012; Lang et al., 1990) and darkness (e.g., Grillon and Ameli, 1998).
Skin conductance response reflects the extent to which the electrical conductance of the skin 
is altered by a state of arousal via increased sweat gland activity (e.g., Lykken and Venables, 
1971). Threat-related increases in skin conductance response have been observed, and these 
have been found to co-occur with engagement of components of the neurocircuitry of threat, 
including the amygdala and medial PFC (e.g., Williams et al., 2001), although dissociation 
of skin conductance and neural fear network activation during fear conditioning has been 
observed (Tabbert et al., 2006). Many studies have incorporated skin conductance response 
as a physiological indicator of acute threat, but some research suggests that it may be a more 
nonspecific measure of arousal that is not as closely tied to threat-related neurocircuitry as 
other physiological indicators, such as fear-potentiated startle (e.g., Lonsdorf et al., 2014). 
Furthermore, differential skin conductance responses in fear conditioning are thought to 
require an awareness of contingencies related to the conditioning paradigm (Hamm and 
Weike, 2005; Tabbert et al., 2006). These differences may explain, at least in part, 
discrepancies in associations between genetic predictors and different physiological 
indicators.
Although not investigated as frequently as fear-potentiated startle or skin conductance 
response, heart rate is a third physiological measure that has been employed in some studies 
of acute threat-related processes. Heart rate, generally measured with pulse oximetry, 
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provides an index of autonomic arousal that parallels brain activity in response to emotional 
stimuli in several regions, including the amygdala and insula (e.g., Critchley et al., 2005).
Genetic Influences on the Physiology of Acute Threat
Heritability
Evidence from twin studies suggests that physiological measures of acute threat are 
heritable. Heritability of fear conditioning based on skin conductance responses has been 
estimated to range between 35-45% (Hettema et al., 2003). Resting heart rate and stress-
induced heart rate reactivity have also been shown to be heritable, with heritability estimates 
of 63% and 52%, respectively, in a sample of middle-aged twins (de Geus et al., 2007). 
Substantial heritability has been demonstrated for overall startle response as well, with 
estimates ranging, on average, from 50-70% (Anokhin et al., 2003; Anokhin et al., 2007; 
Vaidyanthan et al., 2014). However, findings regarding the heritability of emotional 
modulation of the startle response (e.g., fear potentiation of startle) are less consistent. In an 
initial study, Carlson et al. (1997) demonstrated that affectively-modulated startle responses 
showed greater concordance for monozygotic than dizygotic twins, suggesting that 
emotional modulation of startle may be mediated, in part, by genetic factors. However, 
subsequent investigations (Anokin et al., 2007; Vaidyanthan et al., 2014) have found little 
support for heritability of difference scores reflecting affective modulation of startle.
Molecular genetics findings: Candidate gene studies
As with the literature on genetic influences on the neural circuitry of acute threat, nearly all 
of the studies investigating the genetics of acute threat-related physiology have employed 
the candidate gene approach. Lonsdorf and Kalisch (2011) provided a comprehensive 
review of genetic association studies of physiological indicators of fear conditioning and 
extinction. We build on the research discussed in that paper here, discussing candidate genes 
that were investigated in two or more investigations in the text (as above) and emphasizing 
studies that were published in the time since that review (see Table I). The vast majority of 
research has focused on the 5-HTTLPR, COMT Val158Met, and BDNF Val66Met 
polymorphisms, although some additional genes have been examined as well.
Similar to the literature on neural circuits of acute threat, several serotonergic-related genes 
have been examined with respect to threat-related physiology. The 5-HTTLPR 
polymorphism has been the subject of the most research, and, of the different serotonergic 
variants examined, it has received the most robust support for a role in physiological threat 
responses. Across numerous studies, the S allele has been associated with greater 
physiological responding to fearful stimuli compared to the L allele. Findings are most 
robust for startle responses (Armbruster et al., 2009; Klumpers et al., 2012; Klumpers et al., 
2014; Lonsdorf et al., 2009; Wendt et al., 2014; Williams et al., 2009; although see Heitland 
et al., 2013; Larson et al., 2010; Pauli et al., 2010, for exceptions) and less consistent for 
skin conductance response (Crisan et al., 2009; Garpenstrand et al., 2001; Glotzbach-Schoon 
et al., 2013; Hartley et al., 2012; Hermann et al., 2012; Klucken et al., 2014; Klumpers et al., 
2014; Lonsdorf et al., 2009). Some evidence also supports greater emotional task-elicited 
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heart rate among S allele carriers compared to L allele homozygotes (Williams et al., 2009; 
although see Gatt et al., 2009, for an exception).
Greater startle among S allele carriers (vs. L allele homozygotes) has been observed during 
several phases of fear conditioning paradigms, including fear acquisition, reconditioning, 
and extinction (Lonsdorf et al., 2009; Wendt et al., 2014). Additionally, greater resistance to 
extinction has been documented based on skin conductance response in S allele carriers 
compared to those with the L/L genotype (Agren et al., 2012). There is also initial evidence 
that 5-HTTLPR genotype may be linked to fear reacquisition after extinction. Extinction 
training that occurs inside (i.e., 10 minutes), but not outside (i.e., 6 hours), the 
reconsolidation interval has been associated with weakened return of fear (Schiller et al., 
2010). Compared to L allele homozygotes, S allele carriers exhibited greater reacquisition of 
fear (as indicated by skin conductance response) when fear was extinguished outside, rather 
than inside, the reconsolidation interval (Agren et al., 2012). This research provides an 
initial demonstration of 5-HTTLPR allelic differences on fear memory reconsolidation.
Although most investigations have examined the main effect of 5-HTTLPR genotype on 
acute threat physiology, three studies investigated whether 5-HTTLPR genotype might 
interact with life stress to contribute to physiological measures of threat responsivity. 
Williams et al. (2009) found support for a significant 5-HTTLPR Genotype × Early Life 
Stress interaction in predicting heart rate during nonconscious processing of fearful faces, 
such that S allele carriers who reported high levels of early stress exhibited the greatest 
increase in heart rate when subliminally presented with fearful vs. neutral faces. 
Additionally, Hermann et al. (2012) demonstrated that, compared to L allele homozygotes, S 
allele carriers who reported a higher number of traumatic events exhibited stronger skin 
conductance responses during late fear acquisition trials. However, Armbruster et al. (2009) 
failed to find that 5-HTTLPR genotype significantly interacted with multiple measures of 
life stress, including early stress, cumulative lifetime stress, and recent (past 18 months) 
stress, to impact startle response when viewing emotional pictures. Differences between 
these investigations (e.g., emotional stimuli presentation, physiological outcome measure) 
make it challenging to draw conclusions, and thus more research is needed to better 
understand whether 5-HTTLPR genotype is differentially associated with the physiology of 
acute threat as a function of environmental experience.
Nevertheless, overall, a growing literature suggests that the S allele of 5-HTTLPR is 
associated with heightened fear responding at the physiological level. However, some 
inconsistencies in findings across studies may reflect differences in study design and 
measure selection. For example, several studies that used aversive pictures to modulate the 
startle response failed to find an association between 5-HTTLPR genotype and fear-
potentiated startle (e.g., Armbruster et al., 2009; Brocke et al., 2006; Larson et al., 2010; 
Pauli et al., 2010), even though genotype was often related to overall startle response 
(Armbruster et al., 2009; Brocke et al., 2006). In contrast, the S allele of 5-HTTLPR was 
more consistently linked to augmented physiological indicators of threat in studies that used 
Pavlovian fear conditioning paradigms with aversive US (e.g., unpleasant, but not painful, 
electrical stimulation; e.g., Lonsdorf et al., 2009; Wendt et al., 2014). These findings suggest 
that Pavlovian fear conditioning paradigms may produce more robust affective modulation 
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of the startle response. In addition, the greater consistency of findings of 5-HTTLPR 
genotype modulation for startle responses than for skin conductance responses may reflect 
differences in the nature of these two physiological outcomes. As mentioned above, some 
researchers have noted that fear-potentiated startle may be a stronger indicator of amygdala-
driven defensive responding than skin conductance response, which is influenced by 
additional factors that are not specific to reactions to threat, such as cognitive factors related 
to contingency awareness (Lonsdorf et al., 2009; Wendt et al., 2014). Therefore, this pattern 
of results suggests that even though several measures may reflect physiological processes, 
various indicators may tap into different underlying neurobiological pathways and thus show 
different degrees of association with genetic markers. These findings demonstrate the 
importance of conducting cross-cutting research that investigates connections across 
multiple units of analysis in order to better understand the factors that contribute to a given 
outcome measure.
Three studies have also examined variation in MAOA with respect to the physiology of acute 
threat. Compared to the T allele of the rs6323 SNP of MAOA, the G allele has been 
associated with higher MAOA enzyme activity (Hotamisligil and Breakefield, 1991). In one 
investigation, women with the G/G genotype showed greater startle potentiation to 
emotional stimuli than T carriers (Larson et al., 2010). Similarly, among patients with panic 
disorder with agoraphobia, those with the higher expression variant of the VNTR 
polymorphism in the promoter region of MAOA had higher heart rates during a behavioral 
avoidance task designed to provoke anxiety compared to patients with the lower expression 
variant (Reif et al., 2014). These findings provide some initial evidence that higher MAOA 
activity levels may be associated with increased physiological responses to threat, although 
no significant differences in skin conductance response during fear conditioning and 
extinction were observed in another study as a function of MAOA promoter VNTR genotype 
(Garpenstrand et al., 2001).
COMT is also one of the most-studied genes with respect to the physiology of acute threat, 
however findings regarding associations between COMT Val158Met genotype and startle 
response to aversive pictures have been mixed. Montag et al. (2008) found that Met allele 
homozygotes of the Val158Met polymorphism exhibited exaggerated startle to aversive 
pictures compared to Val allele carriers, whereas Klauke et al. (2012) found that Met allele 
homozygotes had a blunted startle response to aversive pictures when compared to Val allele 
carriers. Pauli et al. (2010) failed to detect a significant association between COMT 
genotype and startle responses in an affective picture startle paradigm.
A more cohesive set of findings has emerged from studies employing fear conditioning 
paradigms. Across several investigations, the Val158Met polymorphism has not been 
associated with differential responding during fear acquisition, but Met allele homozygotes 
have been found to show deficits in fear inhibition and extinction and/or greater fear 
memory consolidation. For instance, compared to Val allele carriers, Met allele 
homozygotes showed pronounced startle response during a conditional discrimination 
paradigm despite the presence of a safety signal (Wendt et al., 2014), as well as a greater 
startle response to the CS+ during extinction (Lonsdorf et al., 2009). With respect to fear-
related psychopathology, the Met/Met genotype was associated with increased startle 
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response during fear inhibition trials in individuals with posttraumatic stress disorder 
(PTSD), suggesting that trauma and trauma-related psychopathology may exacerbate these 
genetic deficits (Norrholm et al., 2013). Researchers have suggested that the increased 
dopamine availability among Met allele carriers may underlie deficits in learning safety cues 
(Wendt et al., 2014). Initial evidence from fear reacquisition studies after extinction also 
suggests that Val allele homozygotes may maintain and update fear memories more 
effectively than Met allele carriers. Compared to carriers of the Met allele, individuals with 
the Val/Val genotype responded differentially to a reconsolidation manipulation on 
reacquisition such that they exhibited greater reacquisition of fear (as indicated by skin 
conductance response) when fear was extinguished outside (i.e., 6 hours) rather than inside 
(i.e., 10 minutes) the reconsolidation interval (Agren et al., 2012). Finally, preliminary 
support for a Gene × Environment interaction of COMT genotype with childhood trauma 
was provided by Klauke et al. (2012), who found that, only among Val allele homozygotes, 
greater childhood trauma was associated with increased potentiation of the startle response 
to unpleasant stimuli during an affective picture-startle paradigm.
Most work on dopaminergic-related genes has examined COMT variation, but two studies 
investigated variation in dopamine receptor genes with respect to the physiology of acute 
threat. A VNTR polymorphism in the dopamine receptor D4 (DRD4) gene has been 
associated with dopamine function, with the long repeat variant linked to reduced 
dopaminergic efficiency compared to the short repeat variant (Asghari et al., 1995). Some 
evidence suggests that the long variant of DRD4 was associated with blunted startle 
response to unpleasant stimuli (Pauli et al., 2010) and delayed extinction based on skin 
conductance response (Garpenstrand et al., 2001). However, there was no significant 
difference as a function of DRD4 genotype when comparing good vs. poor fear acquisition 
participants as defined by skin conductance response (Garpenstrand et al., 2001). Initially 
believed to be located in the dopamine receptor D2 (DRD2) gene, the Taq1A restriction 
fragment length polymorphism has also been studied with respect to acute threat physiology. 
Although it has since been determined to be located in the nearby ankyrin repeat and kinase 
domain containing 1 (ANKK1) gene, it is in linkage disequilibrium with DRD2 variants, and 
the A1 allele has been associated with low DRD2 density (Munafò et al., 2007). However, 
no significant associations between ANKK1 Taq1A genotype with startle or skin 
conductance responses during fear conditioning or emotional startle paradigms have been 
detected to date (Huertas et al., 2010; Montag et al., 2008).
Overall, there have been mixed findings regarding BDNF variation and physiological 
measures of acute threat, although some evidence suggests that the Met allele of the 
Val66Met polymorphism is associated with deficient fear-related physiology. For example, 
compared to the Val/Val genotype, the Met allele has been associated with slower or 
impaired extinction based on skin conductance response (Soliman et al., 2010), slower 
learning of safety cues based on skin conductance response (Soliman et al., 2010), a lack of 
fear-potentiated startle responses during late acquisition and early extinction (Lonsdorf et 
al., 2010), and attenuated startle to the CS+ (relative to the CS-) during differential 
conditioning (Hajcak et al., 2009). These findings may, in part, reflect enhanced fear 
memory retrieval. In addition, using a novel paradigm to examine generalization of cued 
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fear across contexts, Mühlberger et al. (2014) observed that only Met allele carriers—and 
not Val allele homozygotes—exhibited potentiated startle responses to the CS+ (vs. the CS-) 
in a novel context (indicative of generalization of fear). There was also a trend for Met allele 
carriers to show worse discrimination of fear vs. safety contexts during acquisition 
compared to Val allele homozygotes based on startle responses. These findings suggest that 
the Met allele may be associated with diminished learning of associations between context 
and conditioned fear. Despite this body of evidence, other studies, including those with large 
sample sizes, have failed to detect significant associations between BDNF Val66Met 
genotype and startle or skin conductance responses during several stages of fear 
conditioning (Lonsdorf et al., 2014, Torrents-Rodas et al., 2012). Furthermore, there is 
preliminary evidence that BDNF genotype in interaction with early life stress may contribute 
to task-elicited increases in heart rate: Among Met allele carriers, high (vs. low) levels of 
early life stress were associated with greater task-elicited heart rate increases (Gatt et al., 
2009).
As in the literature related to the neural circuitry of acute threat, variation in the NPRSR1 
gene and the physiology of acute threat has been investigated as well. No significant 
associations between NPSR1 rs324981 genotype and skin conductance response were found 
in individuals without a history of psychopathology during fear conditioning paradigms 
(Glotzbach-Schoon et al., 2013; Raczka et al., 2010), although an initial finding suggests 
that a link between NPSR1 genotype and threat-related physiology may emerge in 
individuals with panic disorder. In a sample of patients with panic disorder who underwent a 
behavioral avoidance test of being locked in a small dark chamber for up to 10 minutes, T 
allele carriers exhibited greater heart rate compared to A allele homozygotes during 
anticipation of the behavioral avoidance test, exposure, and recovery (Domschke et al., 
2011).
In addition, some sex-specific findings for candidate genes relevant to threat responsivity 
have emerged for physiological measures of acute threat. Variation in the gene coding for 
the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor (ADCYAP1R1), 
which plays a key role in regulating prolonged stress circuit activation (Ressler et al., 2011), 
has been linked to differential startle response in adult women, although the sex-specific 
nature of the association has been found to vary with developmental stage. Specifically, 
compared to G allele carriers, adult women with the C/C genotype of rs2267735 were less 
able to discriminate danger from safety signals (as measured with startle response) during 
late acquisition of fear, and they showed greater dark-enhanced startle (Ressler et al., 2011). 
These genotype-related differences in startle response were not observed in adult men. In an 
investigation of children, C allele homozygotes exhibited greater dark enhanced startle 
compared to G allele carriers, but this finding was detected in both males and females 
(Jovanovic et al., 2013). The finding that C allele homozygote status was associated with 
potentiated startle in both male and female children, but only in adult women, suggests that 
ADCYAP1R1-related vulnerability for acute threat may only be present in females after 
adolescence due to changes in estrogen levels. This is consistent with the location of 
rs2267735 in an estrogen response element, in addition to the finding that ADCYAP1R1 
gene expression is influenced by estrogen (Ressler et al., 2011).
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Gene × Gene interactions—Some research on the physiology of acute fear has also 
begun to investigate the joint contributions of multiple genetic variants. For example, 
several studies have suggested that the combination of the S allele of the 5-HTTLPR 
polymorphism and homozygosity of the Met allele of the COMT Val158Met polymorphism 
is associated with particularly heightened physiological fear responsivity that is resistant to 
extinction and the presence of safety cues (Lonsdorf et al., 2009; Lonsdorf et al., 2011; 
Wendt et al., 2014). Although not studied as extensively as the potential interaction of 5-
HTTLPR with COMT genotype, there is some evidence that the 5-HTTLPR S allele may also 
interact with variation in the corticotropin releasing hormone receptor 1 (CRHR1; the G 
allele of rs878886) and NPSR1 (the T allele of rs324981) genes to contribute to heightened 
startle responses to threatening contexts (Glotzbach-Schoon et al., 2013; Heitland et al., 
2013). Finally, one study detected a significant three-way interaction between early life 
stress and variation in two genetic variants implicated in biological systems that have been 
shown to modulate one another (i.e., the BDNF and serotonergic systems; Homberg et al., 
2014). Specifically, Gatt et al. (2010) found that individuals who were carriers of the Met 
allele of the BDNF Val66Met polymorphism and homozygous for the C allele of the 
rs1062613 SNP in the serotonin receptor 3A (HTR3A) gene who also reported high levels of 
early life stress showed the greatest increases in heart rate in response to an emotional faces 
task. Although highly preliminary, the results of this study suggest that it may be promising 
to consider the joint contributions of related genetic variants and environmental factors 
when trying to elucidate the genetic underpinnings of the acute threat construct.
Molecular genetics findings: Genome-wide association studies (GWAS)
All of the work discussed thus far on molecular genetic influences on both the neural circuits 
and physiology of acute threat has utilized a candidate gene approach. Although some 
findings from this literature have been detected across independent investigations, relatively 
few meet a precise definition of replication (the same SNP, phenotype, and direction of 
association; Sullivan, 2007). Furthermore, there are significant limitations to this 
methodology. For one, with the candidate gene approach, genes are selected for study based 
on their involvement in biological pathways that are hypothesized to be implicated in acute 
threat. Even though the biological underpinnings of acute threat have been studied 
extensively from a translational perspective, with research conducted in animals and humans 
(Shin and Liberzon, 2010), our understanding is far from complete. This thus restricts the 
genes examined to those implicated in a limited number of biological systems. Another 
limitation is that many of the candidate gene studies are characterized by small sample sizes 
and vulnerable to Type I error. Indeed, in their meta-analysis of studies on 5-HTTLPR 
variation and amygdala activation, Murphy et al. (2013) concluded that all the published 
research on this topic has been statistically underpowered.
In recent years, GWAS have become increasingly feasible with the mapping of the human 
genome and advances in high throughput genotyping. In contrast to the candidate gene 
approach, a GWAS implements an agnostic approach that tests for associations between 
variation in hundreds of thousands to millions of SNPs across the genome and a phenotype 
of interest. To date, one GWAS has been published with respect to the physiology of acute 
threat. Vaidyanathan et al. (2014) conducted the first GWAS of startle response in a sample 
Sumner et al. Page 18









of over 3,000 twins and their parents. Over 527,000 SNPs across the genome were 
examined, but no variants exceeded the threshold for genome-wide statistical significance (p 
< 5 × 10-8) for either overall startle response or emotion-modulated startle. Vaidyanathan et 
al. (2014) also conducted a genome-wide scan that analyzed associations between more than 
17,000 autosomal genes with startle responses. These analyses aggregated the contributions 
of all SNPs in a single gene; this is a more powerful approach when there are multiple causal 
variants within a gene. One gene emerged as statistically significant in the analysis of 
aversive modulated startle: the poly (ADP-ribose) polymerase family, member 14 (PARP14) 
gene on chromosome 3, which codes for a protein that aids in injured cell survival (Amé et 
al., 2004). PARP14 has not been implicated in prior work on startle. Thus, notably, the 
genome-wide approach identified a variant in a novel pathway that would not have been 
examined using the biologically-driven candidate gene methodology, thereby highlighting 
the promise of using genome-wide methods for hypothesis generation. Vaidyanathan et al. 
(2014) also examined candidate SNPs that have been associated with startle response in the 
extant literature, and it is noteworthy that none of these SNPs was statistically significant 
after Bonferroni correction in their sample of over 3,000 individuals. The lack of significant 
candidate SNP-based findings in this sample, which far exceeds the sample sizes of studies 
in the candidate gene literature, thus raises some concerns regarding whether published 
findings represent true associations.
Conclusions and Recommendations for Future Research
Even though the RDoC project was only launched in 2009, it has already begun to influence 
the field's conceptualization of psychopathology. Indeed, research aimed at defining 
dimensions of observable behavior and neurobiological measures—across multiple units of 
analysis—that are proposed to cut across diagnostic categories has been accumulating in the 
years since RDoC was initiated. As summarized in this paper, in particular, there is a 
growing body of literature on the genetic influences on the neural circuitry and physiology 
of acute threat. The translational nature of this research is a major strength, as related 
processes have been observed across human and non-human species (Briscione et al., 2014). 
Furthermore, although some genetic variants and outcomes have only been investigated by 
one or (at most) a handful of studies, some findings have emerged that have been observed 
across independent investigations. Specifically, support in the extant literature is most robust 
for associations between the 5-HTTLPR and COMT Val158Met polymorphisms with threat-
related responses across both neural and physiological units of analysis. The 5-HTTLPR S 
and COMT Met alleles have been associated with heightened activation in several 
frontolimbic areas, especially the amygdala, in response to aversive stimuli and with threat-
related physiological responding, particularly potentiated fear acquisition (5-HTTLPR) and 
deficits in fear inhibition or extinction and/or greater fear memory consolidation (COMT). It 
is worth noting, though, that many studies have been statistically underpowered and that 
these two polymorphisms are some of the most widely-studied polymorphisms in all of 
psychiatric genetics. The robustness of findings for different genes thus needs to be 
considered in light of potential publication bias.
Despite these initial findings, our knowledge of the genetic architecture underlying acute 
threat remains limited, and further research is needed to better elucidate this construct across 
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multiple levels of analysis. Here, we make five recommendations for future research that 
aim to extend the growing body of work on this topic and ultimately improve our 
understanding of risk for psychopathology:
1. Test how genetic influences on acute threat-related neural circuitry and physiology 
contribute to the development of psychopathology
The vast majority of the extant literature on genetic influences on the neural and 
physiological bases of acute threat has been conducted in individuals without a history of 
psychopathology, which suggests that the detected associations between genetic variants and 
neural and physiological processes are not dependent upon fear or threat-related 
psychopathology. However, research in samples of individuals with psychiatric conditions is 
needed to better understand how these relations may result in functioning at the extreme end 
of the dimension of acute threat. Longitudinal studies, such as prospective high-risk cohort 
designs, are critical for testing how neural and physiological intermediate phenotypes may 
mediate the association between genetic vulnerability and the development of threat-related 
psychiatric conditions.
2. Continue to study acute threat at multiple levels of analysis
The research on the genetics of the neural and physiological bases of acute threat highlights 
some advantages to examining genetic influences on biological intermediate phenotypes. 
For example, in several studies, studying neural and physiological measures permitted 
detection of associations with genetic variants that did not emerge when investigating self-
report clinical outcomes, such as subjective ratings of fear (e.g., Glotzbach-Schoon et al., 
2013; Heitland et al., 2012; Heitland et al., 2013; Lonsdorf et al., 2009; Klumpers et al., 
2012; Mühlberger et al., 2014; Pauli et al., 2010). Thus, incorporating more objective 
intermediate phenotypes that may lie closer to the underlying biological substrate may prove 
fruitful in elucidating the genetic architecture of dimensions of functioning, like acute threat, 
that are relevant to psychopathology. Moreover, some studies have found that genetic 
variations were significantly associated with neural activation patterns but not with more 
distal measures of symptoms of psychopathology (e.g., Stevens et al., 2014). In addition, 
some research suggests that genotype effect sizes on neural activation patterns are larger 
than effect sizes associated with psychopathology (e.g., Stevens et al., 2013; Stevens et al., 
2014). It is worth noting that some researchers have questioned whether the contributions of 
specific genes to intermediate phenotypes are larger than they are to more complex 
phenotypes, such as psychiatric disorders (e.g., Flint and Munafò, 2007). However, even if 
the genetic architecture underlying intermediate phenotypes does not prove to be simpler 
than that for psychiatric illness, the existing research suggests that studying genetic 
influences on acute threat across multiple units of analysis is advantageous for providing a 
more comprehensive understanding of the factors that contribute to this construct.
Moreover, research that investigates the genetics of acute threat-related processes at multiple 
units of analysis and that examines links across these units in a single investigation has been 
especially encouraging, and more work of this nature is needed. For example, Klumpers et 
al. (2014) demonstrated that increased dorsomedial PFC responses to threat (vs. neutral) 
cues was associated with increased psychophysiological responding to threat, and this neural 
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activation mediated the relation between 5-HTTLPR genotype and both skin conductance 
and startle responses to threat. This kind of research has particular promise for delineating 
how genetic vulnerability translates into behavior.
3. Use genome-wide methods and collaborative consortium efforts
Despite the growing findings on the genetics of acute threat-related neural circuits and 
physiology, the majority of studies have investigated variants of a single candidate gene, and 
this approach has been widely discredited (e.g., Kendler, 2013). Additional GWAS of acute 
threat-related neural circuits and physiology are of interest, particularly for hypothesis 
generation and identifying genetic variants that can then be explored with more targeted 
biological investigations. As described above, Vaidyanathan et al. (2014) provide an 
excellent model for how to comprehensively study variation across the genome with respect 
to a physiological outcome that is relevant to acute threat. Furthermore, GWAS of brain 
activation patterns have been conducted (e.g., Potkin et al., 2009), although not with respect 
to acute threat neural networks.
GWAS have produced fundamental knowledge about the genetic basis of psychiatric 
disorders (along with the methods to extract such knowledge; Sullivan et al., 2012), 
including the landmark paper in Nature which reported on the discovery of 108 genome-
wide significant loci for schizophrenia in ∼36,000 cases and ∼113,000 controls (one of 
NIMH Director Insel's top five findings for 2014; Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014). This knowledge needs to be extended to the 
genetics of acute threat-related neural circuits and physiology. However, GWAS require 
very large sample sizes for signal detection. Indeed, Vaidyanathan et al. (2014) noted that 
their sample of over 3,000 individuals—the largest study of genetic influences on acute 
threat-related physiology to date—was statistically underpowered for their GWAS. 
Collaborative consortium-based efforts, such as that of the Psychiatric Genomics 
Consortium (PGC; e.g., Sullivan et al., 2012) and the Enhancing Neuro Imaging Genetics 
through Meta-Analysis (ENIGMA) Consortium (e.g., Thompson et al., 2014), provide 
encouraging models for combining data from multiple samples and how this can be fruitful 
for identifying genetic variants. The PGC has demonstrated the potential for identifying 
genetic loci that show robust and replicable associations with psychopathology (particularly 
with respect to schizophrenia and bipolar disorder) with sufficiently powered GWAS. There 
are also working groups within the PGC, such as the genetics and imaging group within the 
PTSD working group of the PGC (Logue et al., 2015), focused on studying genetic 
influences on intermediate phenotypes that are relevant to psychopathology, such as neural 
structure and function. In addition, the ENIGMA Consortium is a network of researchers 
working collaboratively to conduct GWAS of brain imaging phenotypes. As part of this 
recently established collaborative effort, these scientists have already begun to identify 
genetic variants associated with brain structures (Hibar et al., 2015; Stein et al., 2012). 
Furthermore, both the PGC and ENIGMA have developed data processing pipelines that 
offer standardized methods for data preparation and analysis that can be used by different 
investigators. We believe that it is critical to employ these kinds of collaborative efforts for 
genome-wide investigations of loci implicated in the neural and physiological bases of acute 
threat. However, GWAS identify genetic variants that are associated with a phenotype, but 
Sumner et al. Page 21









they do not necessarily identify causal variants or underlying mechanisms. Findings from 
GWAS thus need to be followed up with further investigations, such as deep sequencing and 
functional studies, in order to elucidate biological mechanisms.
4. Move beyond common genetic variation and single genetic loci
Both candidate gene and GWAS research have typically studied common genetic variation, 
and developing a diverse collection of genomic assessments, including copy number 
variants (a type of structural variant) and rare variants (both structural and exonic), may also 
deepen understanding of the different factors that comprise genetic contributions to the 
neural and physiological bases of acute threat. Recent methodological advances (e.g., in 
sequencing methods) will contribute to increased feasibility of these pursuits. In addition, 
incorporating the effects of multiple “-omics” data (e.g., GWAS, DNA methylation, and 
gene expression data), rather than only focusing on one level of genetic data, may help to 
shed light on underlying biological mechanisms.
It is also of interest to consider the influence of multiple genetic loci on the neural circuits 
and physiology of acute threat. Intermediate phenotypes are likely to be polygenic in nature, 
and a number of the candidate gene systems investigated in the literature thus far (e.g., the 
serotonergic and BDNF systems; Homberg et al., 2014) have been found to act 
synergistically. Some studies have begun to examine epistatic effects by testing Gene × 
Gene interactions (e.g., Heitland et al., 2013; Wendt et al., 2014), and more research is 
needed, particularly with increased understanding of the underlying biological systems. 
However, sample sizes need to be sufficiently large to have adequate statistical power to 
detect interactions. In addition, polygenic scores for neural and physiological indicators of 
acute threat that aggregate the effects of multiple genetic loci are of interest, particularly as 
more GWAS findings accumulate. Polygenic scores are based on the notion that the role of 
multiple common variants in an outcome may be observed when considered collectively, 
and promising findings based on polygenic scores have emerged in the broader psychiatric 
genetics literature (e.g., International Schizophrenia Consortium, 2009).
5. Consider Gene × Environment interactions
Additional research investigating Gene × Environment interactions has potential for 
enhancing our understanding of the acute threat construct as well. Relatively few studies in 
the extant literature have considered environmental influences on neural and physiological 
measures of acute threat responses in interaction with genetic influences, despite evidence of 
environmental contributions to these outcomes. Research on Gene × Environment 
interactions may be especially helpful for elucidating how genetic vulnerability translates 
into pathological dysfunction of the acute threat dimension. As described in this review, a 
few studies have demonstrated evidence for Gene × Environment interactions in 
contributing to neural and physiological manifestations of acute threat (e.g., Canli et al., 
2006; Gatt et al., 2009). However, further research, particularly work that goes beyond 
cross-sectional study designs, is needed to better understand how mechanisms of risk unfold.
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Returning to the Aim of the RDoC Initiative
A sizeable, and growing, literature has begun to delineate genetic contributions to the neural 
circuits and physiology of acute threat, one of the key constructs of the RDoC framework 
that is relevant to various forms of psychopathology, particularly anxiety and trauma-related 
disorders. In concluding this review, we return to the aim of the RDoC initiative, which is to 
“accelerate the pace of research that translates basic science into clinical settings by 
understanding the multi-layered systems that contribute to mental function” (Chiodo, 2014). 
RDoC is still a relatively nascent initiative, and “biosignatures” of psychopathology that can 
be used to inform clinical intervention efforts remain far off. Nevertheless, we are optimistic 
that research on genetic influences on the neural and physiological bases of acute threat may 
influence the development of precision medicine in the future.
Indeed, initial results in the area of “therapygenetics” suggest that genetic variation may 
influence an individual's response to psychotherapy, and findings related to the genetic bases 
of the neural and physiological bases of acute threat in particular may prove useful for 
informing which patients receive certain therapeutic interventions in the future. For 
example, growing findings suggest that variation in some of the genes discussed in this 
review may inform which patients with panic disorder with agoraphobia are most likely to 
respond to CBT. Patients with panic disorder with agoraphobia with the higher expression 
variant of MAOA showed less of a response to CBT than those with the lower expression 
variant, and this was mirrored at the level of neural responses such that only carriers of the 
lower expression variant showed patterns of neural activation that were indicative of 
improved discrimination between danger and safety signals following completion of CBT 
(Reif et al., 2014). In addition, patients with panic disorder with agoraphobia with the risk 
genotype of HTR1A rs6295 (G/G) participated in fewer self-initiated exposure practices 
during the course of CBT treatment compared to those with the C/C genotype (Straube et al., 
2014). G allele homozygotes also exhibited less of a neural response to CBT, such that CBT 
only impacted the neural correlates of fear learning in C allele, and not G allele, 
homozygotes. These neural changes in C allele homozygotes may have resulted from the 
greater number of exposure practices, although additional research is needed to better 
understand the underlying mechanisms.
Furthermore, research suggests that examining genetic influences on intermediate 
phenotypes, including at the neural level, may be particularly useful for understanding 
individual differences in treatment response. For instance, Lueken et al. (2015) examined 5-
HTTLPR as a predictor of response to CBT in patients with panic disorder with agoraphobia. 
No significant main effect of 5-HTTLPR genotype on treatment response emerged but 
significant associations were detected when neural responsivity during fear conditioning 
prior to the start of treatment was taken into consideration. Lueken et al. (2013) previously 
demonstrated that a negative correlation between ACC and amygdala activation during fear 
conditioning was predictive of responding to CBT, and the authors found that among 
treatment responders, only L allele homozygotes exhibited a negative ACC-amygdala 
coupling. Thus, 5-HTTLPR genotype appeared to modulate a neural pattern of connectivity 
implicated in fear extinction and predictive of treatment response. The findings of this study 
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indicate that particular patterns of neural activity may be relevant for understanding 
treatment response in individuals with a certain genotype.
Together, these findings begin to suggest that information about one's genetic background, 
in addition to individual differences at the neural and physiological levels, may one day be 
utilized to tailor intervention efforts. With its emphasis on studying dimensions of 
functioning across multiple units of analysis, the RDoC initiative encourages the rich 
characterization of psychological processes. We believe that this approach holds promise for 
studying mechanisms of risk for, and resilience to, psychopathology, and that this 
knowledge can ultimately be used to design more targeted and effective mental health 
treatment.
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